BBOT – bridgebio oncology therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Biotech investor Cormorant secures $150M for another SPAC deal [Yahoo! Finance]
Helix Acquisition prices $150M initial public offering [Seeking Alpha]
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is now covered by analysts at Weiss Ratings. They set a "sell (d+)" rating on the stock.
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was upgraded by analysts at Raymond James Financial, Inc. to a "moderate buy" rating.
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Form 8-K Helix Acquisition Corp. For: Jan 22
Form 4 Helix Acquisition Corp. For: Jan 26 Filed by: Chen Bihua
Form 424B4 Helix Acquisition Corp.
Form EFFECT Helix Acquisition Corp.
Form 3 Helix Acquisition Corp. For: Jan 22 Filed by: Schmid John P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.